ING Groep NV Increases Stock Position in Masimo Co. (NASDAQ:MASI)

ING Groep NV increased its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 143.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 240,900 shares of the medical equipment provider's stock after buying an additional 141,900 shares during the period. ING Groep NV owned 0.45% of Masimo worth $32,119,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. KBC Group NV raised its stake in Masimo by 17.3% during the third quarter. KBC Group NV now owns 1,280 shares of the medical equipment provider's stock worth $171,000 after buying an additional 189 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Masimo in the third quarter worth $478,000. Versor Investments LP grew its holdings in Masimo by 81.7% in the third quarter. Versor Investments LP now owns 9,591 shares of the medical equipment provider's stock worth $1,279,000 after purchasing an additional 4,313 shares during the period. State of New Jersey Common Pension Fund D grew its holdings in Masimo by 1.2% in the third quarter. State of New Jersey Common Pension Fund D now owns 16,736 shares of the medical equipment provider's stock worth $2,231,000 after purchasing an additional 194 shares during the period. Finally, Crossmark Global Holdings Inc. grew its holdings in Masimo by 14.4% in the third quarter. Crossmark Global Holdings Inc. now owns 3,248 shares of the medical equipment provider's stock worth $433,000 after purchasing an additional 409 shares during the period. Institutional investors own 85.96% of the company's stock.

Masimo Stock Down 0.9 %

MASI stock traded down $1.53 during trading on Thursday, reaching $160.15. The stock had a trading volume of 855,922 shares, compared to its average volume of 680,305. Masimo Co. has a one year low of $89.18 and a one year high of $173.90. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $136.27 and its two-hundred day moving average is $126.54. The company has a market capitalization of $8.57 billion, a price-to-earnings ratio of 110.38 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period in the prior year, the firm posted $0.63 EPS. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Equities research analysts forecast that Masimo Co. will post 4.04 EPS for the current year.

Analysts Set New Price Targets

MASI has been the subject of a number of research reports. Wells Fargo & Company raised their price target on shares of Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Wednesday, November 6th. Piper Sandler raised their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. Finally, BTIG Research boosted their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Masimo has a consensus rating of "Moderate Buy" and a consensus price target of $163.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.